JAK2 V617F genotyping of blood and bone marrow fractionated cell populations
Patient . | Prognostic Lille score . | Peripheral myeloid cells . | Peripheral lymphoid cells . | Bone marrow mononuclear cells . | CD34+* . | CD34+ CD38+* . | CD34+ CD38−* . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Gr . | Pl . | Mo . | B . | NK . | T . | ||||||
IMF1 | Low | ++ | ++ | ++ | ++ | − | − | ND | ND | ND | ND |
IMF2 | High | ++ | +++ | ++ | ++ | + | − | ND | ++ | ++ | ++ |
IMF3 | High | ++ | ++ | ++ | ++ | ++ | +low | ND | ND | ND | ND |
IMF4 | Int | ++ | ++ | ++ | + | − | − | ND | + | + | + |
IMF5 | Low | + | + | + | − | ND | ND | ND | ND | ND | ND |
IMF6 | Int | ++ | ++ | ++ | − | + | ND | ND | ++ | ++ | ++ |
IMF7 | High | ++ | ++ | ++ | + | ++ | +low | ND | + | + | + |
IMF8 | Int | + | + | + | − | ND | − | ND | ND | ND | ND |
IMF9 | Int | + | + | + | − | − | − | ND | + | + | + |
IMF10 | Int | ++ | ++ | ++ | ++ | ++ | − | ND | ++ | ++ | ++ |
PV1 | NA | ++ | ++ | + | − | − | − | ++ | ++ | ND | ND |
PV2 | NA | ++ | + | + | − | − | − | ND | ND | ND | ND |
PV3 | NA | ++ | ++ | ++ | − | − | − | ++ | ++ | ++ | − |
PV4 | NA | ++ | ++ | ++ | − | − | − | +++ | ++ | ++ | − |
PV5 | NA | ++ | ++ | ++ | − | − | − | +++ | ND | ND | ND |
PV6 | NA | ++ | ++ | + | − | − | − | ++ | + | ++ | − |
PV7 | NA | +++ | ++ | ++ | − | − | − | +++ | ND | ND | ND |
PV8 | NA | +++ | ++ | ++ | − | + | − | ND | ND | ND | ND |
PV9 | NA | +++ | ++ | ++ | + | − | − | ++ | ND | ND | ND |
PV10 | NA | +++ | ++ | ++ | − | − | − | +++ | ++ | ++ | ++ |
PV11 | NA | ++ | ND | ND | ND | ND | ND | ++ | ++ | ++ | + |
PV12 | NA | +++ | ND | ND | ND | ND | ND | +++ | ND | ND | ND |
Patient . | Prognostic Lille score . | Peripheral myeloid cells . | Peripheral lymphoid cells . | Bone marrow mononuclear cells . | CD34+* . | CD34+ CD38+* . | CD34+ CD38−* . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Gr . | Pl . | Mo . | B . | NK . | T . | ||||||
IMF1 | Low | ++ | ++ | ++ | ++ | − | − | ND | ND | ND | ND |
IMF2 | High | ++ | +++ | ++ | ++ | + | − | ND | ++ | ++ | ++ |
IMF3 | High | ++ | ++ | ++ | ++ | ++ | +low | ND | ND | ND | ND |
IMF4 | Int | ++ | ++ | ++ | + | − | − | ND | + | + | + |
IMF5 | Low | + | + | + | − | ND | ND | ND | ND | ND | ND |
IMF6 | Int | ++ | ++ | ++ | − | + | ND | ND | ++ | ++ | ++ |
IMF7 | High | ++ | ++ | ++ | + | ++ | +low | ND | + | + | + |
IMF8 | Int | + | + | + | − | ND | − | ND | ND | ND | ND |
IMF9 | Int | + | + | + | − | − | − | ND | + | + | + |
IMF10 | Int | ++ | ++ | ++ | ++ | ++ | − | ND | ++ | ++ | ++ |
PV1 | NA | ++ | ++ | + | − | − | − | ++ | ++ | ND | ND |
PV2 | NA | ++ | + | + | − | − | − | ND | ND | ND | ND |
PV3 | NA | ++ | ++ | ++ | − | − | − | ++ | ++ | ++ | − |
PV4 | NA | ++ | ++ | ++ | − | − | − | +++ | ++ | ++ | − |
PV5 | NA | ++ | ++ | ++ | − | − | − | +++ | ND | ND | ND |
PV6 | NA | ++ | ++ | + | − | − | − | ++ | + | ++ | − |
PV7 | NA | +++ | ++ | ++ | − | − | − | +++ | ND | ND | ND |
PV8 | NA | +++ | ++ | ++ | − | + | − | ND | ND | ND | ND |
PV9 | NA | +++ | ++ | ++ | + | − | − | ++ | ND | ND | ND |
PV10 | NA | +++ | ++ | ++ | − | − | − | +++ | ++ | ++ | ++ |
PV11 | NA | ++ | ND | ND | ND | ND | ND | ++ | ++ | ++ | + |
PV12 | NA | +++ | ND | ND | ND | ND | ND | +++ | ND | ND | ND |
Prognostic score of IMF patients (Lille score)24 is indicated.
Gr indicates granulocytes; Pl, platelets; Mo, monocytes; +++, samples with > 50% of mutated allele; ++, samples with mutated allele ranging from 25% to 50%; +, samples with 5% to 25% of mutated allele; +low, positive samples with mutated allele at the threshold of detection; −, absence of the JAK2 V617F mutation; ND, no data; NA, not applicable.
CD34+, CD34+CD38+, and CD34+CD38– cells were separated from whole blood in IMF patients, and from bone marrow samples in PV patients.